MetabolicHuman RCT
SURMOUNT-3: what tirzepatide added after a 12-week lifestyle programme
In 579 adults who had already lost weight on a 12-week lifestyle programme, tirzepatide took off a further 18.4% over 72 weeks. Placebo gained 2.5%.
Tirzepatide
A weekly GIP and GLP-1 receptor agonist, licensed for diabetes and weight management, with large randomised trials showing about 20% average weight loss.
- Also known as
- Mounjaro, Zepbound, LY3298176
- Area
- Metabolic
- Status
- Prescription medicine approved in the UK (Mounjaro) and US (Mounjaro, Zepbound)
Articles on Tirzepatide
MetabolicHuman RCT
SURMOUNT-2: how much weight tirzepatide took off in people with type 2 diabetes
In 938 adults with obesity and type 2 diabetes, tirzepatide cut weight by 12.8% to 14.7% over 72 weeks, against 3.2% on placebo.
MetabolicHuman RCT
SURMOUNT-4: what happened to weight when people stopped tirzepatide
After 36 weeks on tirzepatide, 670 adults were randomised to continue or switch to placebo. Weight went down a further 5.5% in one group and up 14.0% in the other.
SleepHuman RCT
SURMOUNT-OSA: tirzepatide cut sleep apnoea events by 20 to 24 an hour more than placebo
In two 52-week trials of adults with obesity and moderate-to-severe sleep apnoea, tirzepatide cut breathing interruptions far more than placebo. Eli Lilly funded both.
MetabolicHuman RCT
SURMOUNT-5: tirzepatide beat semaglutide by 6.5 points of body weight in a 72-week head-to-head
In 751 adults with obesity, tirzepatide cut weight by 20.2% against 13.7% on semaglutide. The trial was open-label and paid for by the maker of tirzepatide.
MetabolicHuman RCT
Retatrutide: what the trials show so far, and what is still a press release
Peer-reviewed trials show 24% weight loss at 48 weeks and large falls in liver fat; the headline 28% phase 3 figure is still company-reported.
MetabolicHuman RCT
Cagrilintide and CagriSema: what the amylin trials found
Alone, cagrilintide cut weight by about 11% in 26 weeks; paired with semaglutide it reached 20% at 68 weeks, but lost a head-to-head against tirzepatide.
MetabolicHuman RCT
SURMOUNT-1: how much weight tirzepatide took off in 72 weeks
At the top dose, people lost 20.9% of their body weight against 3.1% on placebo. Here is who was in the trial, what it cost them in side effects, and what it can’t tell you.
MetabolicHuman RCT
Tirzepatide: what SURMOUNT and SURPASS found
Around 20% average weight loss at 72 weeks, a clear head-to-head win over semaglutide, and heart-outcome data that holds up against an older GLP-1 drug.